Darglitazone is a potent, selective, and orally active PPAR-γ agonist used for the study of type 2 diabetes by effectively regulating glucose and lipid metabolism; it restores euglycemia, normalizes elevated corticosterone, triglycerides, and very-low-density lipoprotein (VLDL) levels, reduces infarct size in diabetic ob/ob mice following hypoxic-ischemic injury, and restores acute cerebral inflammatory responses, thereby significantly improving recovery from hypoxic-ischemic insult.